American Express, Biogen upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: JPMorgan upgraded American Express (AXP) to Overweight from Neutral with a price target of $400, up from $328. The company trades at a slight premium to the group, but this is warranted given the defensive nature of its revenues, the analyst tells investors in a research note. Truist upgraded Biogen (BIIB) to Buy from Hold with a price target of $235, up from $190, ahead of the Phase 2 BIIB080 data presentation at AAIC next week and the approaching Phase 3 pipeline readouts with litifilimab due in Q4. The firm's "increasingly constructive" view on the outlook for Biogen shares is driven by expectations for the unveiling of differentiated, clinically meaningful Phase 2 data with Diranersen, and an attractive risk/reward. Jefferies upgraded Shopify (SHOP) to Buy from Hold with a price target of $160, up from $140. Third party data indicates Shopify's fiscal Q2 results will beat consensus estimates, the analyst tells investors in a research note. Morgan Stanley upgraded Keysight Technologies (KEYS).